Eli Lilly and Company logo

Eli Lilly and Company

TickerLLYVenueUSSectorHealthcarePrimary listingBeta0.50
$1,240-1.33%
FinScore76

Eli Lilly and Company is a United States-based company in the Healthcare sector with a market capitalisation of $1.2T. Its FinScore is 76/100; its highest-scoring layer is Momentum (82) and its lowest is Value (48). The shares trade at 44.3x trailing earnings and are up 16% year to date.

Market cap
$1.2T
P/E (TTM)
44.3x
Dividend yield (TTM)
0.53%
ROE
92.6%

Share price performance

Loading chart…

About Eli Lilly and Company

www.lilly.com

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Profile
Sector
Healthcare
Industry
Drug Manufacturers - General
HQ
United States
Fiscal year-end
December
Trading currency
USD
Reporting currency
USD
Fundamentals updated
75 days ago
Market
Market cap
$1.2T
Shares outstanding
941.4M
P/E (TTM)
44.3x
Dividend yield (TTM)
0.53%
Beta (issuer)
0.45
Revenue (latest FY)
$65.2B

Revenue breakdown

FY 2025$65.2B
  • Product
    93.5%$61.0B
  • Collaboration and Other Revenue
    6.5%$4.2B

FinScore

As of 2026-10-19
Overall76
Quality82
Growth79
Value48
Momentum82
Relative Strength100

Snapshot

Ownership

As of 2026-06-30
Institutional
88.6%
Insider
0.0%
Free float
90.1%
Top-5 institutional holders
33.4%
Shares outstanding
941.4M
Sign up to see the top holders

Sign up or log in to see Analysis

Analysis for Eli Lilly and Company is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Financials

Financials for Eli Lilly and Company is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Estimates

Estimates for Eli Lilly and Company is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Peers

Peers for Eli Lilly and Company is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Valuation

Valuation for Eli Lilly and Company is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see News

News for Eli Lilly and Company is available to Finryse members. The Overview stays open to everyone; creating an account is free.